Orion Oyj (OTCMKTS:ORINY) Hits New 52-Week High – Still a Buy?

Orion Oyj (OTCMKTS:ORINY) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $28.63 and last traded at $28.63, with a volume of 946 shares traded. The stock had previously closed at $28.14.

Analysts Set New Price Targets

Separately, Nordea Equity Research lowered shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Stock Performance

The stock has a market cap of $8.08 billion, a price-to-earnings ratio of 22.72 and a beta of 0.25. The firm has a fifty day simple moving average of $25.06 and a 200 day simple moving average of $25.19. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25.

Orion Oyj (OTCMKTS:ORINY) last issued its earnings results on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. The business had revenue of $463.41 million during the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. As a group, sell-side analysts expect that Orion Oyj will post 1.18 earnings per share for the current year.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.